A systematic review of the gut microbiome, metabolites, and multi-omics biomarkers across the colorectal cancer care continuum
Beneficial Microbes · 14.08.2024 · 15 (6) · 539-563
DOI: 10.1163/18762891-bja00026 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Beneficial Microbes, erschienen am 14.08.2024. Verfasst von Y Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nell Hodgson Woodruff School of Nursing, 1371Emory University, 1520 Clifton Road NE, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colorectal Neoplasms, Metabolome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: Oncology Nursing Society, National Institute of Nursing Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The gut microbiome and the microbial metabolome contribute to treatment efficacy and treatment outcomes across the cancer care spectrum. This study systematically reviewed the existing literature between 2007 to March 2022 to elucidate the role of gut microbiota-metabolite biomarkers in colorectal cancer (CRC) care and treatment-related outcomes. Using Covidence, all studies identified were screened by title and abstract, followed by a full-text review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and data extraction. We analysed 13 non-experimental and 9 experimental CRC studies and found that, usually, the α-diversity of the gut microbiome and short-chain fatty acids decreased in CRC patients, while amino acids (e.g. glutamate) increased in CRC patients. Correlations between specific gut microbial taxa and metabolites were identified, with amino acids, fatty acids, and glycerol positively associated with certain gut microbes. Interventions promoting gut microbes and microbial metabolites associated with better health outcomes (e.g. Bifidobacterium , Lactobacillus , butyric acid, and bile acid) can potentially promote treatment efficacy and improve cancer care outcomes. Gut microbial metabolism should be integrated into targeted cancer interventions for CRC patients, given the confirmed role of the gut microbiome and metabolome pathways across the CRC care continuum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nell Hodgson Woodruff School of Nursing, 1371Emory University, 1520 Clifton Road NE, Atlanta, GA 30322, USA.
- Rollins School of Public Health, 1371Emory University, Atlanta, GA 30322, USA.
- Department of Pediatrics, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
- Winship Cancer Institute, 1371Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Y Wu, N Shen, B N Richardson, M C Swartz, J Bai
Förderung
- Oncology Nursing Society
- National Institute of Nursing Research
Zitieren
APA
Wu, Y., Shen, N., Hope, C., Noh, H. I., Richardson, B. N., Swartz, M. C., & Bai, J. (2024). A systematic review of the gut microbiome, metabolites, and multi-omics biomarkers across the colorectal cancer care continuum. Beneficial Microbes, 15(6), 539-563. https://doi.org/10.1163/18762891-bja00026
Vancouver
Wu Y, Shen N, Hope C, Noh HI, Richardson BN, Swartz MC, et al. A systematic review of the gut microbiome, metabolites, and multi-omics biomarkers across the colorectal cancer care continuum. Beneficial Microbes. 2024;15(6):539-563. doi:10.1163/18762891-bja00026
BibTeX
@article{Wu2024,
author = {Wu, Y and Shen, N and Hope, C and Noh, H I and Richardson, B N and Swartz, M C and Bai, J},
title = {A systematic review of the gut microbiome, metabolites, and multi-omics biomarkers across the colorectal cancer care continuum},
journal = {Beneficial Microbes},
year = {2024},
volume = {15},
number = {6},
pages = {539--563},
doi = {10.1163/18762891-bja00026}
}
EUVIMED